Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ardelyx, Inc.
  6. Summary
    ARDX   US0396971071

ARDELYX, INC.

(ARDX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
1.34(c) 1.28(c) 1.27(c) 1.34(c) 1.31(c) Last
2 338 237 3 352 878 2 795 003 3 266 727 7 784 338 Volume
-1.47% -4.48% -0.78% +5.51% -2.24% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 9,78 M - -
Net income 2021 -138 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,95x
Yield 2021 -
Sales 2022 16,5 M - -
Net income 2022 -106 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,35x
Yield 2022 -
Capitalization 135 M 135 M -
Capi. / Sales 2021 13,8x
Capi. / Sales 2022 8,17x
Nbr of Employees 129
Free-Float 98,7%
More Financials
Company
Ardelyx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines to improve treatment for people with kidney and cardiorenal diseases. The Company's product pipeline includes Tenapanor, IBSRELA, RDX013 Program, and RDX020 Program. The Tenapanor is a medicine for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.... 
More about the company
Ratings of Ardelyx, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about ARDELYX, INC.
09/17KESSLER TOPAZ MELTZER & CHECK, LLP : Reminds Investors of Deadline for Securitie..
PR
09/15ARDX NOTICE : ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investor..
PR
09/10INVESTOR ALERT : Kirby McInerney LLP Reminds Investors That a Class Action Lawsu..
BU
09/06KESSLER TOPAZ MELTZER & CHECK, LLP : Reminds Investors of Securities Fraud Class..
PR
09/05SHAREHOLDER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their..
PR
09/03ARDELYX : Says Tenapanor Demonstrated Therapeutic Potential in Hyperphosphatemia..
MT
09/03Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial
CI
08/30ARDELYX : ROSEN, A TOP RANKED LAW FIRM, Encourages Ardelyx, Inc. Investors with ..
BU
08/29KESSLER TOPAZ MELTZER & CHECK, LLP : Securities Fraud Class Action Filed Against..
PR
08/27SHAREHOLDER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their..
PR
08/26ARDX NOTICE : ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Ardelyx,..
PR
08/26SHAREHOLDER ACTION NOTICE : The Schall Law Firm Reminds Investors of a Class Act..
PR
08/19SHAREHOLDER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their..
PR
08/18ARDELYX : Unveils Plans for Common Stock Offering of up to $150 Million
MT
08/17ARDELYX : OPEN MARKET SALE AGREEMENT1 (Form 8-K)
PU
More news
News in other languages on ARDELYX, INC.

- No features available -

More news
Analyst Recommendations on ARDELYX, INC.
More recommendations
Chart ARDELYX, INC.
Duration : Period :
Ardelyx, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARDELYX, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 1,31 $
Average target price 4,75 $
Spread / Average Target 263%
EPS Revisions
Managers and Directors
Michael G. Raab President, Chief Executive Officer & Director
Justin A. Renz Chief Financial & Accounting Officer
David M. Mott Chairman
Jeffrey W. Jacobs Chief Scientific Officer
Elizabeth Grammer Secretary, Chief Legal & Administrative Officer
Sector and Competitors
1st jan.Capi. (M$)
ARDELYX, INC.-79.75%135
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850